April 16, 2018 / 6:07 AM / 7 months ago

BRIEF-Herantis Pharma Announces Positive Interim Data From Lymfactin Study

1 Min Read

April 16 (Reuters) - HERANTIS PHARMA OYJ:

* REG-HERANTIS PHARMA ANNOUNCES POSITIVE INTERIM DATA FROM LYMFACTIN STUDY IN SECONDARY LYMPHEDEMA

* PHASE 1 STUDY CONTINUES WITH A 12-MONTH FOLLOW-UP ON PATIENTS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below